{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:46:13Z","timestamp":1759333573272},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T00:00:00Z","timestamp":1205280000000},"content-version":"vor","delay-in-days":6555,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>2\u2032,5\u2032 oligoadenylate (2\u20105A) synthetase mRNA and enzyme levels have been studied in peripheral blood mononuclear cells from 12 patients with chronic granulocytic leukaemia (CGL), 14 with essential thrombocythaemia (ET) and nine with chronic lymphocytic leukaemia (CLL), undergoing therapy with alpha interferon (\u03b1IFN). 2\u20105A synthetase mRNA was assayed by hybridization using the dot\u2013blot technique and the enzyme activity was measured biochemically. A statistically significant difference was observed (<jats:italic>P<\/jats:italic>&lt;0\u00b705) between the degree of <jats:italic>in vivo<\/jats:italic> induction of mRNA by IFN\u03b1 in the total patients between the good and intermediate responders and the poor responders. There was a similar pattern in each of the CGL, ET and CLL groups although this only reached statistical significance in the CGL group. In <jats:italic>vitro<\/jats:italic> induction of either mRNA or of enzyme activity, however, did not show a difference between the responders and poor responders in any of the patient groups. Our findings are consistent with the concept that 2\u20105A has an important role in the anti\u2010tumour activity of \u03b1IFN and suggest that measurement of <jats:italic>in vivo<\/jats:italic> induction of 2\u20105A synthetase mRNA may be useful in predicting clinical response. <jats:italic>In vitro<\/jats:italic> studies, on the other hand, do not provide a reliable predictor of clinical response.<\/jats:p>","DOI":"10.1111\/j.1365-2141.1990.tb06334.x","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T13:45:34Z","timestamp":1205329534000},"page":"452-456","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Alpha interferon therapy for haematological malignancies: correlation between <i>in vivo<\/i> induction of the 2\u2032,5\u2032 oligoadenylate system and clinical response"],"prefix":"10.1111","volume":"74","author":[{"given":"W. C. P. de","family":"Mel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Hoffbrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ganeshaguru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,12]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"317","article-title":"Effects of tumour necrosis factor and \u03b1 interferon on chronic B\u2010cell malignancies","volume":"30","author":"Bianchi A.C.M.","year":"1988","journal-title":"Nouvelle Revue Francaise d'Hematologie"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0771-050X(86)80045-6","article-title":"Qualitative differences in effects of recombinant alpha\u2010, beta\u2010, and gamma\u2010interferon on human peripheral blood leukocytes in vitro","volume":"137","author":"Billard C.","year":"1987","journal-title":"Annals of the Institute of Pasteur, Immunology"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(98)80003-9"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(84)90339-7"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91782-5"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(83)90418-9"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90429-2"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04275.x"},{"key":"e_1_2_1_10_1","unstructured":"Heslop H.E. Bianchi A.C.M. Cordingley F.T. Turner M. deMel W.C.P. Hoffbrand A.V.&BrennerM.K.(1990)Mechanism of action of \u03b1 interferon in B\u2010lymphoproliferative disorders. (Submitted.)."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01315699"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.1.256"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.51.070182.001343"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_2_1_15_1","volume-title":"Molecular Cloning: A Laboratory Manual.","author":"Maniatis T.","year":"1982"},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood.V67.4.937.937","article-title":"B\u2010cell growth factor induced proliferation of hairy cell lymphocytes and inhibition by type 1 interferon in vitro","volume":"67","author":"Paganelli K.A.","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880301)61:5<869::AID-CNCR2820610503>3.0.CO;2-I"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V67.2.275.275","article-title":"Treatment of multiple myeloma with recombinant \u03b1 interferon","volume":"67","author":"Quesada J.R.","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","article-title":"Treatment of hairy cell leukemia with recombinant DNA\u2010derived interferon alpha: a phase II study","volume":"68","author":"Quesada J.R.","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_20_1","first-page":"4848","article-title":"In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha\u2010interferon: correlation with receptor binding and induction of 2\u2032,5\u2032\u2010oligoadenylate synthetase","volume":"46","author":"Rosenblum M.G.","year":"1986","journal-title":"Cancer Research"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1985.tb03848.x"},{"key":"e_1_2_1_22_1","first-page":"310","article-title":"Recombinant leukocyte A interferon in B\u2010cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity","volume":"4","author":"Schulor R.S.","year":"1985","journal-title":"Journal of the Biology of Respiration and its Modifications"},{"key":"e_1_2_1_23_1","first-page":"62","article-title":"Therapy of chronic myelogenous leukaemia: chemotherapy and interferons","volume":"25","author":"Talpaz M.","year":"1988","journal-title":"Seminars in Haematology"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830240403"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.2.11.1436"},{"key":"e_1_2_1_26_1","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.V73.6.1426.1426","article-title":"Favorable response of early stage B\u2010CLL patients to treatment with IFN\u2010\u03b12","volume":"73","author":"Ziegler\u2010Heitbrock H.W.L.","year":"1989","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.1990.tb06334.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.1990.tb06334.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T17:03:18Z","timestamp":1697994198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.1990.tb06334.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1111\/j.1365-2141.1990.tb06334.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.1990.tb06334.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,4]]},"assertion":[{"value":"2008-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}